Diagnostics Drags on Guidance, While Strong Orders and Core Business Resilience Support Outperform Rating

Overview

The report reviews Siemens Healthineers' fiscal 2025/26 third-quarter results and updates its earnings model. Group revenue growth was below expectations, with the diagnostics business under significant pressure due to structural adjustments in China's in-vitro diagnostics market and declines in legacy platforms in Europe and the Americas; meanwhile, Imaging and Precision Therapy maintained growth, and the equipment book-to-bill ratio was strong. The company lowered its revenue growth guidance but raised current-period EPS guidance due to a one-off tariff refund. Bernstein maintains its Outperform rating, but lowers forward earnings forecasts and the target price.

Core views

The core view is that the company's business performance continues to diverge: Diagnostics remains the main weakness in the portfolio and is unlikely to escape the impact of China volume-based procurement-related market adjustments and legacy platform declines in the near term; Imaging benefits from adoption of high-end technologies such as photon-counting CT and DryCool MRI, and some third-quarter delivery delays are expected to be released in the fourth quarter; Precision Therapy, driven by Advanced Therapies and Varian, remains one of the strongest growth engines. Fiscal 2026/27 will face tax-rate normalization, refinancing costs, standalone operating costs after separation from Siemens, and inflationary pressure, but tariff mitigation, product upgrades, and strong orders can provide partial offsets.

Analysis framework

The report updates the revenue and EPS model by combining quarterly results versus market expectations, growth and margins by business and region, management's full-year and fourth-quarter guidance, book-to-bill ratio, and earnings headwinds; valuation uses a weighted P/E and discounted cash flow approach, with potential return measured by the 12-month target price.

Methodology notes

• Relative valuationP/E valuation

  Applies a 17.0x P/E multiple based on fiscal 2026/27 adjusted EPS and assigns it a 70% weight in the target price.

  This method reflects the company's forward earnings power and the valuation multiple the market assigns to medical technology companies.

• Absolute valuationDiscounted cash flow valuation

  The discounted cash flow analysis uses an 8% weighted average cost of capital and a 3% perpetual growth rate, and assigns it a 30% weight in the target price.

  This method supplements relative valuation through the discounted value of future cash flows, reducing the impact of a single P/E assumption.

• Operating momentum analysisBook-to-bill ratio

  Assesses visibility into future revenue conversion through the ratio of equipment orders to current-period equipment revenue.

  The third-quarter equipment book-to-bill ratio was 1.27x, and 1.17x excluding long-term partnership projects, showing strong order demand in the core business.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Siemens Healthineers AG (SHL.GR)

  The German-listed stock directly covered by the report

  Strengths

  Strong equipment book-to-bill ratio, continued penetration of high-end imaging technologies, relatively rapid growth in Precision Therapy and Varian, and solid free cash flow performance.

  Weaknesses

  Diagnostics revenue and margins declined significantly, and underlying earnings are affected by tariffs, exchange rates, business mix, and cost pressure.

  Comparison

  The €44.50 target price is 20% above the reference closing price of €37.03; the Outperform rating is based on expected performance relative to the European market benchmark over the next 12 months.

  Risks

  Structural adjustments in China's diagnostics market, decline of legacy platforms in Europe and the Americas, cost inflation, refinancing costs, and standalone operating costs may continue to pressure earnings.

• Imaging

  The company's core imaging business segment

  Strengths

  Photon-counting CT, DryCool MRI, and the radiopharmaceuticals business are growing well, with strong order momentum.

  Weaknesses

  Third-quarter revenue grew only 2.3%, the China market declined, and margins excluding the tariff refund fell year over year.

  Comparison

  Growth was weaker than Precision Therapy, but is expected to accelerate to high-single-digit growth in the fourth quarter, driven by catch-up in MRI deliveries.

  Risks

  Delivery timing, tariffs, cost inflation, and weak China demand may affect revenue realization and margins.

• Diagnostics

  The company's in-vitro diagnostics business segment

  Strengths

  Cost reductions from the transformation plan and growth in Asia Pacific and Japan provide some support.

  Weaknesses

  Third-quarter comparable revenue declined 5.5%, adjusted EBIT margin fell from 9.2% in the prior-year period to 4.1%, and the China market and legacy platforms continued to drag.

  Comparison

  It is the weakest-performing business among the three core segments; Bernstein expects fiscal 2025/26 revenue to decline 5.2% and margin to be only 2.6%.

  Risks

  China volume-based procurement-related structural adjustments, decline of the legacy platform installed base, unfavorable business mix, and exchange-rate pressure may persist.

• Precision Therapy

  The company's precision therapy business segment

  Strengths

  Third-quarter growth was 9.2%, with strong contributions from Advanced Therapies and Varian, and regional growth was broadly based overall.

  Weaknesses

  Margin excluding the tariff refund was 14.1%, slightly below 14.4% in the prior-year period, and Varian faces a higher comparison base.

  Comparison

  It is currently the fastest-growing core business, significantly above the group's third-quarter growth rate of 2.8%.

  Risks

  Tariffs, platform launch progress, volatility in Asia Pacific and China markets, and a high base may affect growth sustainability.

Key data

• Third-quarter revenue€57.64 hundred millionComparable growth of 2.8%, 170 basis points below market expectations of 4.5%.
• Third-quarter adjusted EBIT margin19.1%15.4% excluding the tariff refund, 10 basis points above market expectations of 15.3%.
• Third-quarter adjusted EPS€0.70€0.55 excluding the tariff refund, about 4% above market expectations of €0.53.
• Free cash flow€10 hundred millionAbout €8 hundred million excluding the tariff refund.
• Equipment book-to-bill ratio1.27x1.17x excluding long-term partnership projects.
• Full-year comparable revenue growth guidance3.5% to 4.0%Previous guidance was 4.5% to 5.0%; the cut was mainly due to continued weakness in the diagnostics business.
• Full-year adjusted EPS guidance€2.35 to €2.45Previously €2.20 to €2.30; the increase mainly reflects a one-off U.S. tariff refund.
• Third-quarter Diagnostics growth-5.5%Adjusted EBIT margin was 4.1%, or 3.0% excluding the tariff refund, versus 9.2% in the prior-year period.
• Third-quarter Imaging growth2.3%Adjusted EBIT margin was 26.5%, or 21.6% excluding the tariff refund.
• Third-quarter Precision Therapy growth9.2%Varian comparable growth was 9.3%; the segment's adjusted EBIT margin was 17.6%, or 14.1% excluding the tariff refund.
• Fiscal 2026/27 adjusted EPS forecast€2.36About 5% growth versus the fiscal 2025/26 forecast excluding the tariff refund, but down 8% from the prior forecast after the model update.
• Target price and upside€44.50, 20%Target price lowered from €45.70; the reference closing price is €37.03 on July 31, 2026.

Impact & implications

The revenue guidance cut confirms that structural pressure in the diagnostics business will continue, and the one-off tariff refund means the current EPS upgrade does not fully represent an improvement in underlying earnings. Short-term share-price catalysts mainly come from fourth-quarter catch-up in Imaging deliveries, conversion of strong orders, and Precision Therapy growth; medium-term returns depend on stabilization of the diagnostics business, execution of the tariff mitigation plan, and inflation control. Based on the reference closing price of €37.03, the €44.50 target price still offers 20% potential upside, so Bernstein maintains a positive rating while lowering the valuation.

Risks

• Structural adjustments in China's in-vitro diagnostics market and the impact of volume-based procurement may last longer than expected.
• Rising costs for memory chips, some raw materials, and logistics may offset the benefits of tariff mitigation.
• Tax-rate normalization, higher refinancing costs, and standalone operating costs after separation from Siemens will pressure fiscal 2026/27 EPS.
• Regulatory actions may restrict product sales or production.
• New technology R&D or product pipeline progress falling short of expectations may weaken market position.
• A slowdown in market demand caused by pressure on healthcare budgets may affect equipment and consumables sales.
• Exchange-rate fluctuations, especially a stronger U.S. dollar versus the euro, may affect earnings and valuation.
• The one-off tariff refund lifts current-period profit and may mask pressure on underlying margins.

What to watch

• Whether delayed MRI deliveries in the fourth quarter can drive high-single-digit growth in the Imaging business.
• Whether the revenue declines and margins of the Diagnostics business in China, Europe, the Middle East and Africa, and the Americas can stabilize.
• The actual pace at which the 1.27x equipment book-to-bill ratio converts into revenue and cash flow.
• Progress on the company's plan to fully mitigate about €4 hundred million of tariff impact by fiscal 2027/28.
• Whether inflation in memory chips, raw materials, and logistics offsets the benefits of tariff mitigation.
• The launch of Varian's new radiotherapy platform and delivery of its high-single-digit growth target.
• The final impact of fiscal 2026/27 tax rate, net interest expense, and standalone operating costs.
• The adoption pace of photon-counting CT and DryCool MRI and their contribution to Imaging margins.